Alan L. Fuchsberg, Esq
Mr Fuchsberg is Managing Partner of the Jacob D. Fuchsberg Law Firm and member of the Board of Trustees at New York University School of Law, both in New York, NY. He is the author of several articles on specific matters of civil litigation, including “Challenging 9/11 Victims Fund Rules.”
Karen Katen
Ms Katen is Chair of the Pfizer Foundation, the company’s philanthropic arm devoted to supporting healthcare access, education, and community outreach initiatives around the world. She recently retired as Vice Chairman of Pfizer Inc. and as President of Pfizer Human Health. Ms Katen joined Pfizer in 1974 after receiving her BA and MBA from the University of Chicago, an institution she now serves as a University Trustee and a council member of its Graduate School of Business.
Karen is a director on the boards of the General Motors Corporation and the Harris Corporation. She also serves on the Catalyst Board, the RAND Corporation’s Health Board of Advisors, and the Economic Club of New York Board of Trustees.
She has served on several health care–related boards, including as Treasurer for PhRMA, an industry association representing America’s research-based pharmaceutical companies, and the National Alliance for Hispanic Health. She was also a member of the Healthcare Leadership Council and was active on a variety of international policy bodies, including as Chairman of the US-Japan Business Council.
Her work and accomplishments have received wide recognition. In 2005, Karen was named among the top ten in Fortune Magazine’s ranking of “50 Most Powerful Women in Business,” a list that has included her for eight consecutive years. For her commitment to community and improving public health, she has received 11 distinct “Woman of the Year” or similar awards from civic groups, national association, and universities.
Andrew R. Marks, MD
[LINK to: http://www.markslab.columbia.edu/index.html[Note: Pop-up window copy notifies viewers that they are leaving ARMGO Web site.]
Dr Marks is Chair of the Department of Physiology and Biophysics and Director of the Clyde and Helen Wu Center for Molecular Cardiology, College of Physicians and Surgeons, Columbia University, in New York, NY.
Dr Marks is the Chair of ARMGO’s Scientific Advisory Board. He is a member of the National Academy of Sciences and the Institute of Medicine of the National Academies and a fellow of the American Academy of Arts and Sciences. He is a recipient of the American Heart Association Basic Research Award for his work in developing the first successful drug-eluting stent for treatment of coronary artery stent restenosis and for elucidation of mechanisms causing heart failure and sudden cardiac death.
Felix G. Rohatyn
Ambassador Rohatyn is senior advisor to Chairman and Chief Executive Officer Richard S. Fuld Jr and chairman of the Lehman Brothers’ International Advisory Committees, a position he has held since August 2006. Before joining Lehman Brothers, Ambassador Rohatyn was president of Rohatyn Associates LLC, a firm that he founded in April 2001, which provides financial advice to corporations.
Mr Rohatyn served as United States Ambassador to France from September 1997 until December 2000. Prior to this appointment, Ambassador Rohatyn was a managing director at the investment banking firm Lazard Frères & Co. LLC in New York, which he joined in 1948, becoming a partner in 1961. He retired from Lazard in 1997 in order to take up his post as ambassador. In addition, from 1975 to 1993 he was Chairman of the Municipal Assistance Corporation of the State of New York, where he managed the negotiations that enabled New York City to resolve its financial crisis in the late seventies. He also served as a member of the Board of Governors of the New York Stock Exchange from 1968 to 1972. Ambassador Rohatyn has served on numerous corporate boards in the U.S. and Europe, and currently serves on the Board of LVMH Moët Hennessy Louis Vuitton, Publicis Groupe SA, and Groupe Lagardère.
Ambassador Rohatyn is Vice Chairman of Carnegie Hall, New York City, a member of the Board of Trustees of Middlebury College in Vermont, and a trustee of the Center for Strategic and International Studies in Washington, DC. He is also a member of the Council on Foreign Relations and the American Academy of Arts and Sciences. He has been awarded numerous honorary degrees and is a Commander in the French Legion of Honor.
Ambassador Rohatyn received his Bachelor of Science degree in physics from Middlebury College in 1949.
Andrew Schiff, MD
Dr Schiff currently serves as a Managing Director of Aisling Capital II, LLC and the Perseus-Soros biopharmaceutical fund. He joined the fund in September of 1999. Prior to joining the fund, Dr Schiff practiced internal medicine at The New York Presbyterian Hospital where he maintains his position as a Clinical Assistant Professor of Medicine.
He currently serves on the board of directors of ARMGO Pharma, Inc., Cardiokine, Dynova, Skinmedica, Cempra, and Sirion.
Dr Schiff received his MD from Cornell University Medical College and his MBA from Columbia University. His bachelor’s degree in neuroscience was awarded with honors by Brown University.
Andrew R. Marks, MD
[LINK to: http://www.markslab.columbia.edu/index.html[Note: Pop-up window copy notifies viewers that they are leaving ARMGO Web site.]
Dr Marks is Chair of the Department of Physiology and Biophysics and Director of the Clyde and Helen Wu Center for Molecular Cardiology, College of Physicians and Surgeons, Columbia University, in New York, NY.
Dr Marks is the Chair of ARMGO’s Scientific Advisory Board. He is a member of the National Academy of Sciences and the Institute of Medicine of the National Academies and a fellow of the American Academy of Arts and Sciences. He is a recipient of the American Heart Association Basic Research Award for his work in developing the first successful drug-eluting stent for treatment of coronary artery stent restenosis and for elucidation of mechanisms causing heart failure and sudden cardiac death.
Jeffrey S. Borer, MD
Dr Borer is the Gladys and Roland Harriman Professor of Cardiovascular Medicine and Professor of Cardiovascular Medicine in Radiology at Cornell University Medical College in New York, NY. He directs a wide-ranging program of cardiovascular research focusing on the biology of regurgitant valvular diseases and the use of radioisotopes in evaluating coronary artery disease. In addition, he directs a program of clinical service in cardiology at The New York Hospital-Cornell Medical Center. He has received numerous awards and peer recognition in the form of service on major journal editorial boards, on standing committees of professional organizations, and in visiting professorships and lectures at national and international meetings. Currently, he serves on the editorial boards of nine major peer-reviewed journals and is a permanent visiting professor to the Chinese Academy of Medical Sciences. Borer recently received an award from the Israel National Heart to Heart Association. Since 1984, he has served on NASA advisory committees, and since 1997 on advisory and consulting panels for the US Food and Drug Administration. He has authored or coauthored more than 250 journal articles and book chapters. Borer received his undergraduate education from Harvard, his medical degree from Cornell, and his postgraduate training in internal medicine from Massachusetts General Hospital.
Ronald Breslow, PhD
Dr Breslow is Professor of Chemistry, one of twelve University Professors, and a former Chairman of the Department, all at Columbia University in New York, NY. He is a member of the US National Academy of Sciences, the American Academy of Arts and Sciences, and the American Philosophical Society. He is an Honorary Member of many international societies of chemistry, science, and technology.
Recently he has developed a new group of cytodifferentiating agents with use in cancer chemotherapy. One of these agents is now marketed in the United States to treat a form of blood cancer.
His scientific awards include the American Chemical Society Award in Pure Chemistry, the Fresenius Award, the Baekeland Medal, the Centenary Medal, the Harrison Howe Award, the Remsen Prize, the Roussel Prize in Steroids, the James Flack Norris Prize, the Richards Medal, the Arthur C. Cope Award, the Kenner Award, the Nichols Medal, the National Academy of Sciences Award in Chemistry, the Allan Day Award, the Paracelsus Medal of the Swiss Chemical Society, and the U.S. National Medal of Science. He was named one of the top 75 contributors to the chemical enterprise in the past 75 years by a poll conducted by Chemical & Engineering News, and won the Priestley Medal, the New York City Mayor's Award in Science, the Bader Award in Bioorganic Chemistry and the Esselen Award for Chemistry in the Public Interest. In 2003 he received the Robert Welch Award in Chemistry, and in 2004 he received the Willard Gibbs Award.
He has also received the Mark Van Doren Medal of Columbia University and the Columbia University Great Teacher Award. He was President of the American Chemical Society in 1996. The American Chemical Society has established the annual Ronald Breslow Award in Biomimetic Chemistry.
Kim Fox, MD
Dr Fox is Consultant Cardiologist and Director of Cardiology at the Royal Brompton Hospital in London, UK, Professor of Clinical Cardiology at the Imperial College London, and President of the European Society of Cardiology.
Dr Fox has published more than 400 papers in leading scientific journals. His expertise is in the understanding, investigation, and treatment of angina; he has played a major role in many important international clinical trials (EUROPA, HPS, ASCOT, etc) that have revolutionized the treatment of this condition. He is the acknowledged European expert in this field and consequently chairs the Task Force producing the European Angina Guidelines and chairs the committee responsible for the audit of the management of these patients in Europe.
Professor Fox has given plenary lectures to National Societies all over the world. He has given the “Finlayson Lecture” to the Royal College of Surgeons in Glasgow, the “St Cyres Lecture” to the British Cardiac Society and the “Andrea Cissalpino Lecture” to the Italian Society of Cardiology. Professor Fox has been elected an honorary member of the French Cardiac Society and Japanese Circulation Society for his services to cardiology.
Joseph L. Goldstein, MD
Dr Goldstein is currently Chairman of the Department of Molecular Genetics at the University of Texas Southwestern Medical Center at Dallas. In 1985, he was named Regental Professor of the University of Texas. He also holds the Paul J. Thomas Chair in Medicine and the Julie and Louis A. Beecherl Distinguished Chair in Biomedical Science.
Dr Goldstein and his colleague, Michael S. Brown, discovered the low density lipoprotein (LDL) receptor and elucidated how these receptors control cholesterol homeostasis. At the basic level, this work opened the field of receptor-mediated endocytosis, and at the clinical level it helped lay the conceptual groundwork for development of drugs called statins that lower blood LDL-cholesterol and prevent heart attacks. Drs Goldstein and Brown shared many awards for this work, including the Lasker Award in Basic Medical Research (1985), the Nobel Prize in Physiology or Medicine (1985), and the National Medal of Science (1988).
In recent work, Drs. Goldstein and Brown discovered the sterol regulatory element binding protein (SREBP) family of transcription factors and showed how these membrane-bound molecules control the synthesis of cholesterol and fatty acids through a newly described process of Regulated Intramembrane Proteolysis. For this work, Drs Brown and Goldstein received the Albany Medical Center Prize in Medicine and Biomedical Research (2003).
Dr Goldstein is currently Chairman of the Albert Lasker Medical Research Awards Jury and is a member of the Boards of Trustees of the Howard Hughes Medical Institute and The Rockefeller University. He also serves on the Scientific Advisory Boards of the Welch Foundation, Memorial Sloan-Kettering Cancer Center, Scripps Research Institute, Van Andel Institute, and the Massachusetts General Hospital. He is a member of the US National Academy of Sciences and a Foreign Member of the Royal Society.
Donald W. Landry, MD, PhD
Dr Landry is Professor of Medicine at, Director of the Division of Experimental Therapeutics, and Interim Chair of the Department of Medicine, all at Columbia University in New York, NY. Dr Landry completed his PhD in organic chemistry under Nobel laureate Robert Burns Woodward at Harvard University in 1979 and then obtained an MD degree from Columbia University in 1983. After a residency in internal medicine at the Massachusetts General Hospital, he returned to Columbia University as a National Institutes of Health Physician-Scientist from 1985 to 1990. In 1991, he established his laboratory at Columbia University to investigate medical applications of artificial enzymes and founded the Division of Experimental Therapeutics in 1998, which focuses on novel therapeutics for intractable problems such as cocaine addiction, nerve gas intoxication, and vasodilatory shock. He directs the Organic Chemistry Collaborative Center, a drug discovery unit within the Division.
Raymond John Lipicky, MD
Dr Lipicky is the Director of LIPICKY, LLC (a consulting company), having retired (March 2002, after 21 years of service) from the US Food and Drug Administration (FDA), where he was Director, Division of Cardio-Renal Drug Products, Office of Drug Evaluation I, Center for Drug Evaluation and Research. Previously, he was on the faculty of the University of Cincinnati College of Medicine (for 14 years), where he held the positions of Professor of Pharmacology and Professor of Medicine and Director, Division of Clinical Pharmacology at the time he joined the FDA. He is a graduate of the University of Cincinnati College of Medicine and trained in Internal Medicine and Cardiology. He currently also has an appointment as Visiting Scientist at the Marine Biological Laboratory (Woods Hole, MA) where, for about 30 years, he had a summer laboratory pursuing an interest in drug effects on electrically-excitable membranes, although his laboratory is no longer active.
Douglas L. Mann, MD
Dr Mann is the Don W. Chapman Chair and Professor of Medicine and Molecular Physiology and Biophysics at Baylor College of Medicine, Chief of Cardiology at Baylor College of Medicine, St. Luke’s Episcopal Hospital and the Texas Heart Institute, and Director of the Winters Center for Heart Failure Research. His research interests have focused on the basic cellular and molecular mechanisms that lead to cardiac decompensation, including the role that inflammatory mediators play in regulating cardiac structure and function.
Dr Mann is a member of the American Society for Clinical Investigation, the Association of University Cardiologists, the Heart Failure Society of America, the International Cytokine Society, and the International Society for Heart Failure Research and is a Fellow of the American College of Cardiology as well as the American College of Chest Physicians. He is a member of the Editorial Board of Circulation, The Journal of Cardiac Failure, Heart and Vessels, Heart Failure Reviews, Heart Failure Monitor and Cardiology Today. Dr Mann has published numerous peer-reviewed articles on the role on inflammatory mediators in heart failure and the molecular and cellular basis for cardiac dysfunction and remodeling. He has received numerous awards, including the Alfred Soffer Award for Editorial Excellence from the American College of Chest Physicians and the Michael E. Debakey Award for Excellence in Research.
| |
|
| |
PRIVACY POLICY: |
| |
Purpose of the Privacy Statement. ARMGO™ respects the privacy of visitors to this Web site and understands that information about you, your health, and your health care is sensitive. |
| |
ARMGO™ developed this Internet Privacy Statement to provide information about our practices regarding the collection, use, and disclosure of information that you may provide when you visit this Web site. |
| |
We encourage you to read this Internet Privacy Statement before using this Web site or submitting information. By using this Web site, you acknowledge that you understand and agree to the terms of the Internet Privacy Statement. |
| |
Information Voluntarily Provided by Users. You can visit much of the Web site without telling us who you are or providing us with other personally identifiable information. Some areas of the Web site allow you to contact us to ask questions or provide comments. When you communicate with us and request a response, we ask for your name and contact information. We intend to let you know how we will use such information before we collect it from you; if you tell us that you do not want us to use this information to make further contact with you beyond fulfilling your requests, we will respect your wishes. |
| |
Some areas of the Web site may also require that you submit information in order to access specific content, features, interactive tools, services or participate in a particular activity. For example, to create an online account or to subscribe to a newsletter, we may ask for your name, contact information, and perhaps additional information so we can tailor our response to your request. |
| |
In addition, when you access certain interactive tools or services, you may be asked to provide personally identifiable information. You may always choose not to provide the required information, but then you may not be able to participate in the particular activity that requires the information. |
| |
Use and Disclosure of Your Personally Identifiable Information That You Provide Voluntarily. We may personalize and customize this Web site for certain visitors. |
| |
If you provide information about yourself via a contact form, you may find it customized with references to products and/or services that we believe may be of interest to you, based on your previous interactions and information you have provided to us. |
| |
If you do provide us with personally identifiable information, such as your name, postal address, e-mail address, telephone number, or other information such as your education level, or personal medical information, you agree that we may contact you through a variety of means such as postal mail, phone, or e-mail to provide you with information we believe may be of interest to you unless you opt out of this service by contacting us as indicated below. |
| |
If you do not opt out of this service, we may also share this information with providers of services who help ARMGO™ to develop programs and provide services that may be of interest to you, or for information processing, mailing, and/or Internet-based delivery purposes. |
| |
ARMGO™ will not sell or rent your personally identifiable information. |
| |
Use and Disclosure of Non-Personally Identifiable Information. ARMGO™ will not treat as confidential any information that you provide that is not personally identifiable, such as questions, comments, ideas, or suggestions. You should be aware that ARMGO™ will be free to disclose through any means and use for any purpose such information in its sole discretion. |
| |
By providing such information to ARMGO™, you understand and agree that no relationship has been created between ARMGO™ and you, and ARMGO™ has no obligation to you whatsoever regarding that information. |
| |
Update and Correction of Personally Identifiable Information. You may contact us to update or correct much of your personally identifiable information that you provide to us through the Web site other than the limited information described below under the Regulatory Requirements section, or to opt-out from our mailings and other services that you may have signed up for. To do so, please contact us at (212)352-7000. |
| |
Security. We take reasonable precautions to maintain the protection of personally identifiable information collected through this Web site and used in accordance with this Privacy Statement. In addition to technical safeguards, we also use physical controls and procedures to safeguard your personally identifiable information. However, we cannot guarantee that it is completely secure from people who might attempt to evade our security measures or intercept transmissions over the Internet. |
| |
Use of Cookies. We may store some information on your computer using a technique your browser supports called "cookies". The cookies are used for a variety of purposes, including but not limited to helping you login (e.g., remembering your user name if you register or login), remembering some of your customized user preferences, to help us better understand how people use our Web site, and to help us improve our Web site. In some cases, this information will help us tailor content to your interests or help us avoid asking for the same information when you revisit our Web site. The cookies set by our Web sites are used only by our Web sites. To disable or limit the use of cookies, please refer to the options provided by your Internet browser. If you do so, however, some pages on this Web site may not work properly. |
| |
Web Beacons. A Web Beacon is a clear GIF (Graphics Interchange Format) image or pixel tag (also known as a "Web beacon") that companies place on their Web sites to allow an Internet advertising or audience measurement company to help them analyze their advertising campaigns and general usage patterns of visitors to their Web sites. ARMGO™ may use Web beacons on some sections of its Web site. ARMGO™ will not sell or rent your personally identifiable information. |
| |
Web Server Logging and IP Addresses. With or without cookies, our Web site keeps track of usage data, such as the source address that a page request is coming from (i.e., your IP address, domain name), date and time of the page request, the referring Web site (if any), and other parameters in the URL (e.g., search criteria). We use this data to better understand Web site usage on the whole and to determine which areas of our Web site users prefer (e.g., based on the number of visits to those areas). This information is stored in log files and is used by ARMGO™ for statistical reporting |
| |
Transfer of Control. Circumstances may arise where we decide to reorganize or divest part or all of our business or of a line of our business, including our information databases and Web sites, through a sale, divestiture, merger, acquisition, or other means of transfer. In any such circumstance, personally identifiable information may be shared with, sold, transferred, rented, licensed or otherwise provided or made available by us or on our behalf to actual or potential parties to, and in connection with, the contemplated transaction (without your consent or any further notice to you). In such circumstances, we will seek written assurances that personally identifiable information submitted through this Web site will be protected appropriately. |
| |
Privacy Policies Governing Linked Web Sites. As a convenience to our visitors, the Web site contains links to other Web sites that may offer useful information. The Internet Privacy Statement described here does not apply to your use of those other Web sites. Before using the linked Web sites, please review their Internet privacy statements to understand how they use and protect personally identifiable information. |
| |
Changes in Our Privacy Statement. ARMGO™ may at any time revise this privacy statement by updating this posting. You are bound by any such revisions and should therefore periodically visit this page to review the most current privacy statement. |
| |
Questions. If you have any questions about the Web site’s Internet Privacy Statement or other aspects of privacy on our Web site, please contact us at (914)425-0002. |
